Companion Diagnostics And Deal-making On The Stage At PSA
This article was originally published in The Pink Sheet Daily
Executive Summary
Panelists at Elsevier’s Pharmaceutical Strategic Alliances conference say the need for companion diagnostics and biomarkers, particularly in oncology, are influencing deal-making negotiations and raising questions about how to define the value of a diagnostic test relative to the therapeutic.
You may also be interested in...
Pfizer’s Xalkori Joins The Six-Figure Oncology Drug Club
The roll-out of Pfizer Inc.’s new personalized non-small cell lung cancer therapy Xalkori blends right in with the prevailing trends in cancer drug launches, proving that six-figure pricing now seems to be the new black in oncology.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.